LS in 2022 update: Dec 7th, 2022 Investor Updat
Post# of 153802
(Total Views: 436)
Posted On: 10/03/2024 10:08:59 PM
LS in 2022 update:
Dec 7th, 2022 Investor Update:
Pg 23
HIV reference future development:
" and earlier line HIV indications "
Pg 88:
Leronlimab + "monkey-ize" plus LS Mutation = Long Acting Leronlimab
Pg 97:
1. Prevention of HIV
2. Functional Cure
( control of Viremia )
______
* At least 2 yrs ago, very short mention of LL-PLS being designed.
* Viremia is a medical condition that occurs when viruses enter the bloodstream, giving them access to the rest of the body. The term comes from combining the word "virus" with the Greek word for "blood".
Dec 2022 corporate update & Oct 2024 LL-PLS publication, reference:
HIV
Zika
Viremia
Congenital Diseases
God speed.
Dec 7th, 2022 Investor Update:
Pg 23
HIV reference future development:
" and earlier line HIV indications "
Pg 88:
Leronlimab + "monkey-ize" plus LS Mutation = Long Acting Leronlimab
Pg 97:
1. Prevention of HIV
2. Functional Cure
( control of Viremia )
______
* At least 2 yrs ago, very short mention of LL-PLS being designed.
* Viremia is a medical condition that occurs when viruses enter the bloodstream, giving them access to the rest of the body. The term comes from combining the word "virus" with the Greek word for "blood".
Dec 2022 corporate update & Oct 2024 LL-PLS publication, reference:
HIV
Zika
Viremia
Congenital Diseases
God speed.
(1)
(0)